FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307148839> ?p ?o ?g. }

• W4307148839 endingPage "e342" @default.
• W4307148839 startingPage "e342" @default.
• W4307148839 abstract "<h3>Purpose/Objective(s)</h3> There is limited evidence on the real-world use of pembrolizumab therapy post-approval in 1L R/M HNSCC. The study estimated real-world time on treatment (rwToT) of pembrolizumab monotherapy and pembrolizumab + platinum + 5-fluorouracil for 1L R/M HNSCC patients, stratified by ECOG PS. <h3>Materials/Methods</h3> This retrospective study of the nationwide de-identified electronic health record (EHR)-derived Flatiron Health Advanced H&N database selected patients initiating pembrolizumab monotherapy or pembrolizumab + platinum + 5-fluorouracil between 07/01/19 - 12/31/20 with follow-up until 07/31/21. Patients with prior platinum-based therapy ≤6 months, prior primary cancers, or treatment with a clinical study drug were excluded. rwToT was defined as length of time between first and last documented administration date pembrolizumab. Patients with a record of next line of therapy, death, or treatment gap ≥120 days from the last administration date were considered discontinued. Patients without a discontinuation event were censored at the end of follow up. Kaplan-Meier analysis was conducted to assess median rwToT and landmark on-treatment rates. All results were stratified by ECOG PS 0-1 (similar to KEYNOTE-048, the registrational clinical trial) and ECOG PS 2-3. <h3>Results</h3> A total of 402 patients initiated 1L treatment with pembrolizumab therapy. Of those patients, 297 (73.9%) had a recorded ECOG PS score, majority with an ECOG PS score of 0/1 (Overall: 77.8%, pembrolizumab monotherapy: 70.5%, pembrolizumab + platinum + 5-fluorouracil: 84.1%). The median rwToT was higher among the ECOG 0/1 patients compared to ECOG 2/3 patients for both regimens (pembrolizumab monotherapy: 4.4 vs 2.2 months, pembrolizumab + platinum + 5-fluorouracil: 5.0 vs 3.5 months). <h3>Conclusion</h3> In the real-world, treatment duration with pembrolizumab monotherapy or pembrolizumab+platinum+5-fluorouracil in 1L R/M HNSCC was similar to KEYNOTE-048, when restricted to a trial-matched population of ECOG PS 0-1 patients. Treatment duration tended to be shorter in the real-world ECOG PS 2/3 population, who are commonly excluded from clinical trials." @default.
• W4307148839 created "2022-10-28" @default.
• W4307148839 creator A5020733580 @default.
• W4307148839 creator A5053417759 @default.
• W4307148839 creator A5086656564 @default.
• W4307148839 creator A5091143902 @default.
• W4307148839 date "2022-11-01" @default.
• W4307148839 modified "2023-09-24" @default.
• W4307148839 title "Real-World Time on Treatment Analysis of Pembrolizumab Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients Stratified by ECOG PS in the United States" @default.
• W4307148839 doi "https://doi.org/10.1016/j.ijrobp.2022.07.1436" @default.
• W4307148839 hasPublicationYear "2022" @default.
• W4307148839 type Work @default.
• W4307148839 citedByCount "0" @default.
• W4307148839 crossrefType "journal-article" @default.
• W4307148839 hasAuthorship W4307148839A5020733580 @default.
• W4307148839 hasAuthorship W4307148839A5053417759 @default.
• W4307148839 hasAuthorship W4307148839A5086656564 @default.
• W4307148839 hasAuthorship W4307148839A5091143902 @default.
• W4307148839 hasConcept C121608353 @default.
• W4307148839 hasConcept C126322002 @default.
• W4307148839 hasConcept C141071460 @default.
• W4307148839 hasConcept C143998085 @default.
• W4307148839 hasConcept C2776530083 @default.
• W4307148839 hasConcept C2776833033 @default.
• W4307148839 hasConcept C2777701055 @default.
• W4307148839 hasConcept C2778715236 @default.
• W4307148839 hasConcept C2780057760 @default.
• W4307148839 hasConcept C71924100 @default.
• W4307148839 hasConceptScore W4307148839C121608353 @default.
• W4307148839 hasConceptScore W4307148839C126322002 @default.
• W4307148839 hasConceptScore W4307148839C141071460 @default.
• W4307148839 hasConceptScore W4307148839C143998085 @default.
• W4307148839 hasConceptScore W4307148839C2776530083 @default.
• W4307148839 hasConceptScore W4307148839C2776833033 @default.
• W4307148839 hasConceptScore W4307148839C2777701055 @default.
• W4307148839 hasConceptScore W4307148839C2778715236 @default.
• W4307148839 hasConceptScore W4307148839C2780057760 @default.
• W4307148839 hasConceptScore W4307148839C71924100 @default.
• W4307148839 hasIssue "3" @default.
• W4307148839 hasLocation W43071488391 @default.
• W4307148839 hasOpenAccess W4307148839 @default.
• W4307148839 hasPrimaryLocation W43071488391 @default.
• W4307148839 hasRelatedWork W2020823099 @default.
• W4307148839 hasRelatedWork W2792600153 @default.
• W4307148839 hasRelatedWork W2963491961 @default.
• W4307148839 hasRelatedWork W2980510993 @default.
• W4307148839 hasRelatedWork W3000701650 @default.
• W4307148839 hasRelatedWork W3090002302 @default.
• W4307148839 hasRelatedWork W3103265772 @default.
• W4307148839 hasRelatedWork W3154280247 @default.
• W4307148839 hasRelatedWork W3210496311 @default.
• W4307148839 hasRelatedWork W4283523414 @default.
• W4307148839 hasVolume "114" @default.
• W4307148839 isParatext "false" @default.
• W4307148839 isRetracted "false" @default.
• W4307148839 workType "article" @default.